CNS Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

CNSP$3.85-2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2023 and 2022

Balance Sheets

	December 31, 2023	December 31, 2022
Assets
Current Assets:
Cash and cash equivalents	$548,721	$10,055,407
Deferred offering costs	202,859	–
Prepaid expenses and other current assets	839,590	2,509,238
Total current assets	1,591,170	12,564,645
Noncurrent Assets:
Prepaid expenses, net of current portion	104,750	482,806
Property and equipment, net	4,933	5,664
Total noncurrent assets	109,683	488,470
Total Assets	$1,700,853	$13,053,115
Liabilities and Stockholders' Equity (Deficit)
Current Liabilities:
Accounts payable and accrued expenses	$5,832,162	$4,510,291
Notes payable	300,806	409,968
Total current liabilities	6,132,968	4,920,259
Total Liabilities	6,132,968	4,920,259
Commitments and contingencies	–	–
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	–	–
Common stock, $0.001 par value, 75,000,000 shares authorized and 6,214,598 and 1,617,325 shares issued and outstanding, respectively	6,214	1,617
Additional paid-in capital	65,128,574	58,846,916
Accumulated deficit	(69,566,903)	(50,715,677)
Total Stockholders' Equity (Deficit)	(4,432,115)	8,132,856
Total Liabilities and Stockholders' Equity (Deficit)	$1,700,853	$13,053,115

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.